Target intelligence / Profile preview

Local vaginal immune recognition pathways

Molecular classification
Receptor, Other
01

Overview

Local vaginal immune recognition pathways encompass the complex network of pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and NOD-like receptors (NLRs), that monitor the cervicovaginal environment for pathogens (Wira et al., 2011, Nature Reviews Immunology). These pathways are primarily located on vaginal epithelial cells and resident immune cells, where they detect pathogen-associated molecular patterns (PAMPs) from bacteria, viruses, and fungi (Hickey et al., 2011, Journal of Reproductive Immunology). Upon activation, these pathways trigger the production of cytokines, chemokines, and antimicrobial peptides to initiate a local immune response (Ghosh et al., 2014, American Journal of Reproductive Immunology). While essential for defense against sexually transmitted infections (STIs) like HIV and HSV-2, dysregulation of these pathways can lead to chronic inflammation or increased vulnerability to infection (Anahtar et al., 2015, Immunity). Therapeutic strategies often focus on modulating these pathways using TLR agonists like imiquimod or probiotics to restore a healthy immune balance and prevent disease transmission (StatPearls, 2023). However, excessive activation can lead to mucosal inflammation, which may paradoxically increase the risk of HIV acquisition by recruiting target T-cells to the vaginal mucosa (Passmore et al., 2016, Journal of the International AIDS Society).

Other names
Vaginal mucosal immunityVaginal innate immune recognitionVaginal pattern recognition receptor pathwaysVaginal immune sensingCervicovaginal immune recognition
02

Mechanism of action

Modulation of pattern recognition receptors (PRRs) to enhance or regulate local innate and adaptive immune responses against pathogens.

03

Biological functions

Immune responseInnate immunitySignal transductionPathogen recognitionCell signaling
04

Disease associations

InfectionInflammationHuman immunodeficiency virus (HIV) infectionHuman papillomavirus (HPV) infectionBacterial vaginosisSexually transmitted infection
05

Safety considerations

Mucosal inflammationIncreased susceptibility to HIV acquisitionEpithelial barrier disruptionTissue irritationMicrobiome dysbiosis
06

Interacting drugs

Imiquimod

4 more in the full profile.

07

Biomarkers

Interleukin-8 (IL-8)Interleukin-1 beta (IL-1β)Secretory leukocyte protease inhibitor (SLPI)Vaginal alpha-defensinsMacrophage inflammatory protein-1 alpha (MIP-1α)

Beyond the preview

Go deeper on Local vaginal immune recognition pathways.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Local vaginal immune recognition pathways.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call